Improvements in atopic dermatitis symptoms were seen in children taking dupilumab, with minimal adverse events.
Dupilumab (Dupixent; Sanofi and Regeneron) is safe and effective in treating atopic dermatitis (AD) in pediatric patients, according to a recent review.
Trials have proven dupilumab to be safe and effective for pediatric use, but proper analysis of real world dupilumab use has not been recorded.
To determine the long-term efficacy of dupilumab, researchers gathered medical records from March 2017 to September 2022 of pediatric patients with moderate to severe AD.
Information on patients’ demographics, body surface area (BSA), Eczema Area and Severity Index (EASI), and Investigator's Global Assessment (IGA) were collected.
Almost 90 patients were observed, and all saw a 75% improvement in EASI after at least 1 year of dupilumab use, with about 60% of patients seeing a 90% improvement.
Improvements were also seen in BSA and IGA. Patients with a positive history of atopy saw a greater improvement in BSA from weeks 12 to 24.
Adverse events were seen in about 14% of patients, with the most common being conjunctivitis and joint pain. No serious adverse events were observed.
This article originally appeared on Contemporary Pediatrics.
Reference
Pagan AD, David E, Ungar B, Ghalili S, He H, Guttman-Yassky E. Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: areal-world, single-center study. J Allergy Clin Immunol Pract. 2022;10(9):2378-2385. doi: 10.1016/j.jaip.2022.06.014
FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Atopic Dermatitis
April 29th 2024The ADORING 3 phase 3 development program is currently studying the novel, aryl hydrocarbon receptor agonist as a once-daily, cosmetically elegant, and steroid-free topical cream for adults and children with atopic dermatitis.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Examining the State of Benzoyl Peroxide-Containing Acne Products After Benzene Contamination
April 10th 2024Christopher Bunick, MD, PhD, FAAD, an associate professor of dermatology and a physician-scientist at the Yale School of Medicine in New Haven, Connecticut, presented updates on benzene in BPO at the 2024 American Academy of Dermatology Annual Meeting.